Latest Lucentis news
Repeated Ranibizumab Doesn’t Impair Macular Perfusion
by modernClinician Editorial Team
For patients with diabetic macular edema, repeated ranibizumab treatment does not appear to be associated with impaired macular perfusion, according to a study published online March 1 in JAMA Ophthalmology.
Aflibercept, Ranibizumab Not Cost-Effective Vs. Bevacizumab
by modernClinician Editorial Team
Compared with bevacizumab, aflibercept and ranibizumab are not cost-effective for diabetic macular edema, according to research published online June 9 in JAMA Ophthalmology.
AAO: Ranibizmab Noninferior to Panretinal Photocoagulation
by modernClinician Editorial Team
Treatment with ranibizumab is noninferior to panretinal photocoagulation for eyes with proliferative diabetic retinopathy, according to a study published online Nov. 13 in the Journal of the American Medical Association. The research was published to coincide with the annual meeting of the American Academy of Ophthalmology, held from Nov. 14 to 17 in Las Vegas.
Randomized Trial of Early Vitrectomy Feasible for Postoperative Endophthalmitis 
Vascular Burden in Midlife Linked to Increased Risk for Dementia, Death 
GLP-1 Receptor Agonists Tied to Increased Risk for Alopecia 
Food-Based Support Aids Type 2 Diabetes Outcomes 
Hypoglossal Nerve Stimulation May Offer Long-Term Cardiovascular Benefits in OSA 
Burden of Myocardial Dysfunction Elevated for Individuals With Psoriasis 
2017 to 2022 Saw More Than Doubling in Use of GLP-1 Receptor Agonists 
Chronic Kidney Disease Prevalence Stable From 2013 to 2023 Monthly Specialist Briefings
Stay Connected
